Cardio Diagnostics receives Nasdaq bid price deficiency notice; 180-day cure period until Dec 2, 2024

Cardio Diagnostics Holdings, Inc.

Received Nasdaq notice on June 3, 2024 for non-compliance with minimum bid price rule (below $1.00 for 30 consecutive days).
Has 180 calendar days, until December 2, 2024, to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant by Dec 2, may be eligible for additional 180-day period if other listing standards are met.
Company may consider reverse stock split to cure deficiency; no assurance of regaining compliance.
Notice has no immediate effect on listing or trading of common stock or warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.